BNP Paribas Financial Markets
CMPX icon

BNP Paribas Financial Markets’s Compass Therapeutics CMPX Stock Holding History

BNP Paribas Financial Markets’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78K Sell
35,631
-137
-0.4% -$404 ﹤0.01% 4682
2026
Q1 		$189K Buy
35,768
+20,123
+129% +$116K ﹤0.01% 4076
2025
Q4 		$84K Sell
15,645
-3,878
-20% -$17.9K ﹤0.01% 4452
2025
Q3 		$68.3K Buy
19,523
+10,038
+106% +$31.7K ﹤0.01% 4461
2025
Q2 		$24.7K Sell
9,485
-1,647
-15% -$3.4K ﹤0.01% 4512
2025
Q1 		$21.2K Sell
11,132
-7,430
-40% -$19.8K ﹤0.01% 4525
2024
Q4 		$26.9K Buy
+18,562
New +$30.8K ﹤0.01% 4643

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BNP Paribas Financial Markets's CMPX Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Compass Therapeutics (CMPX) stake by 0.38% in Q2 2026, selling an estimated $404 and leaving 35,631 shares worth $78K. The position accounts for ﹤0.01% of the portfolio, ranked #4682.

BNP Paribas Financial Markets first reported a position in CMPX in Q4 2024 and has held it in 7 quarters since. The position peaked at $189K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • BNP Paribas Financial Markets held 35,631 shares of Compass Therapeutics worth $78K as of Q2 2026.
  • BNP Paribas Financial Markets sold 137 Compass Therapeutics shares in Q2 2026, an estimated $404.
  • Compass Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4682 holding.
  • BNP Paribas Financial Markets first reported a position in Compass Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Compass Therapeutics position peaked at $189K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.